Trial Profile
To compare the anatomical and functional outcomes in patients with macular edema due to central retinal vein occlusion treated with Ranibizumab or Aflibercept
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Sep 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Retinal oedema
- Focus Adverse reactions; Therapeutic Use
- 28 Sep 2017 New trial record